Kornimate/medical-research-clean huggingface dataset:
effectiveness of pragmatic shoulder technique vs traditional physical therapy

Conditions: Shoulder Pain; Shoulder Impingement; Shoulder Injuries; Frozen Shoulder; Shoulder Capsulitis

Summary: isolated and combined effectiveness of pragmatic protocols on shoulder range of motion had been investigated and found effective in healthy participants. to our knowledge, there was insufficient literature to support the comparison between pragmatic and traditional protocols in the treatment of shoulder pathologies.

different physical therapy treatments are being used for shoulder pathologies which include modalities (hot pack, tens), rom exercises, stretching, strengthening, soft tissue mobilization and set of pragmatic manual techniques.the set of pragmatic manual therapies are novel techniques (comprises of acromioclavicular mobilization, serratus anterior stretch, thoracic manipulation, rc facilitation, and pcs) and its isolated effectiveness on rom in healthy subjects has been investigated and found effective. these studies recommended the use of a pragmatic protocol for the prevention and rehabilitation of shoulder injuries and pathologies (unpublished data).as per our knowledge there is insufficient literature to support the comparison of the effectiveness of a set of pragmatic protocols with traditional interventions. our research is proposed to compare the efficacy of pragmatic interventions with that of traditional interventions in patients with shoulder pathology and their effect on the quality of life.

Eligibility criteria:
inclusion criteria: * functional movement score 1 and 2 or limitation in range of motion of abduction, internal rotation, external rotation, rubb, and rdbn. all or only one of the limitations in comparison with the unaffected shoulder joint. exclusion criteria: * patients with shoulder instability. functional movement score 3 and 0. individuals with recent fractures of fewer than 6 weeks duration. cancerous growth around the shoulder girdle. breast cancer and undergoing chemotherapy and radiotherapy. ra arthritis patients. long-term use of steroids and severe osteoporosis.

Keywords: pragmatic intervention, shoulder pathologies, shoulder pain, shoulder range of motion pragmatic shoulder intervention,
dual release hydrocortisone versus conventional glucocorticoid replacement therapy in hypocortisolism (dream)

Conditions: Primary Adrenal Insufficiency; Secondary Adrenal Insufficiency

Summary: this is a randomized, controlled, open, three-armed, multi-centre study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on anthropometric parameters, metabolic syndrome, infectious, immunological profile, cardiovascular system, bone mass and quality of life in patients affected by primary or secondary adrenal insufficiency.

hypocortisolism is a disease with more than 80% 1-year mortality before the availability of synthetic glucocorticoids. current replacement therapy has improved this dramatically, but recent data suggest that outcome is still compromised. patient receiving conventional glucocorticoids therapy have compromised quality of life, reduced bone mass, increased risk factors for cardiovascular disease, infectious, tumors and premature mortality that is more than twice the mortality rate in the background population. circulating cortisol levels follow a distinct diurnal pattern with high levels in the early morning and low trough values around midnight. using available formulations for replacement therapy this circadian rhythm is had to mimic and also during the active time of the day high peaks and low troughs occur. in this trial a dual-release hydrocortisone preparations that has in healthy volunteers been able to mimic the circadian pattern of circulating cortisol was studied in patients with primary and secondary adrenal insufficiency.

Eligibility criteria:
inclusion criteria: * previously diagnosed (e.g. more than 6 months ago) primary or secondary adrenal insufficiency with a stable daily glucocorticoid substitution dose for at least 3 months prior to study entry * signed informed consent to participate in the study exclusion criteria: * acute primary or secondary adrenal insufficiency * clinical or laboratory signs of significant cerebral, cardiovascular, respiratory, hepatobiliary, pancreatic disease * clinically significant renal dysfunction * any medication with agents which could interfere with glucocorticoid kinetics

Keywords: plenadren addison's disease hydrocortisone cortisone acetate monocytes natural killer cells immunological profile inflammation
fundamental asynchronous stimulus timing sound coding study

Conditions: Sensorineural Hearing Loss

Summary: the fundamental asynchronous stimulus timing (fast) is a novel cochlear implant sound coding strategy. potential benefits include improved battery life, in addition to improved localization for bilateral patients.

the fundamental asynchronous stimulus timing (fast) strategy offers excellent potential as a low power alternative coding strategy to the current default strategy in nucleus® cochlear implants, advanced combination encoder (ace). additionally, fast offers potential bilateral benefits - localization and listening in spatially separated noise - because it has been shown in acute, controlled studies to provide more access to interaural timing difference (itd) cues (smith, 2010).previous research with experienced cochlear-implant recipients has shown issues with conversion from ace to fast. the fast strategy typically sounds very different in quality, and acclimatization can be lengthy. this extended adaptation time makes it difficult to show conclusively that fast is non-inferior to ace for speech understanding. a potential barrier to evaluating performance with fast in current cochlear-implant recipients is the extensive amount of prior experience that many recipients have using ace. hence, there is a distinct need to evaluate fast in newly implanted recipients.

Eligibility criteria:
inclusion criteria * medical and audiological candidate for a unilateral ci24re, ci512 or ci532 series implant * post-linguistically deafened * native speaker of american english * eighteen years of age or older exclusion criteria * previous or existing cochlear-implant recipient * pre-linguistically deafened (onset of hearing loss at less than two years of age) * ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array * diagnosis of retro-cochlear pathology * diagnosis of auditory neuropathy * unrealistic expectations on the part of the subject regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure and use of the prosthetic device * unwillingness or inability to comply with all investigational requirements * additional cognitive handicaps that would delay rate of improvement with the cochlear implant

Keywords: cochlear implant, sensorineural hearing loss
cerebral oximetry in newborns - comparing invos 5100 and fore-sight cerebral oximeters

Conditions: Near Infrared Spectroscopy

Summary: regional tissue oxygenation (rsto2) can be monitored by near infrared spectroscopy. the commercial devices fore-sight (casmed) and invos (covidien) will be used simultaneously to test for their relative sensitivity for low oxygen levels just after birth on term infants born by elective cesarean section. reproducibility will be examined by replacements of the sensors six times the next day when the infant is stable and quiet. neonatal sensors will be used.


Eligibility criteria:
inclusion criteria: * term infants (age more than 37 weeks of gestation) * elective cesarean section after an uncomplicated pregnancy exclusion criteria: * thick hair that makes good measurements difficult/impossible * obvious malformations or syndrome * complications in relation to the cesarean section * depression after birth (apgar \< 8 after 1 minute)

Keywords: cerebral oximetry near infrared spectroscopy fullterm infant
post-marketing surveillance study of aripiprazole in patients with autism

Conditions: Autism

Summary: the purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in japan.


Eligibility criteria:
inclusion criteria: * diagnosed as autism with irritability exclusion criteria: * patients who has ever been treated with aripiprazole
the effect of ai-based microbiome diet on ibs-m symptoms

Conditions: Irritable Bowel Syndrome Mixed

Summary: this study was designed as a pilot, open-labelled study. we enrolled consecutive ibs-m patients (n=25, 19 females, 46.06 ± 13.11 years) according to rome iv criteria. fecal samples were obtained from all patients twice (pre- and post-intervention) and high-throughput 16s rrna sequencing was performed. patients were divided into two groups based on age, gender and microbiome matched. six weeks of ai-based microbiome diet (n=14) for group 1 and standard ibs diet (control group, n=11) for group 2 were followed. ai-based diet was designed based on optimizing a personalized nutritional strategy by an algorithm regarding individual gut microbiome features. an algorithm assessing an ibs index score using microbiome composition attempted to design the optimized diets based on modulating microbiome towards the healthy scores. baseline and post-intervention ibs-sss (symptom severity scale) scores and fecal microbiome analyses were compared.


Eligibility criteria:
inclusion criteria: * diagnosed with ibs by a medical doctor. * bmi between 18.5-39.9 kg/m2 * no hospitalization in the last 12 months. * no antibiotics use in the last 6 months. * no cancer diagnosis by a medical doctor. * no chronic complex diseases including diabetes and hypertension. exclusion criteria: * not being diagnosed with ibs. * having a diagnosed chronic disease. * having a diagnosed mental or psychiatric disorder . * having endocrinal disorders. * being pregnant. * antibiotics use in the last 6 months. * hospitalization history in the last 12 months. * drug use. * being morbid obese.
a study to assess immune response following zoster vaccination to subjects with rheumatoid arthritis receiving tofacitinib or placebo with background methotrexate

Conditions: Rheumatoid Arthritis

Summary: this study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.


Eligibility criteria:
inclusion criteria: * subjects must have moderate to severe rheumatoid arthritis inadequately controlled by methotrexate as defined by the american college of rheumatology (acr) classification criteria for rheumatoid arthritis, painful and swollen joint counts and c-reactive protein (crp). * screening crp \>3 mg/l or cdai score \> 10 at screening or at baseline before vaccination. * subjects must have active disease at screening and baseline. * must be at least 50 years of age or older. exclusion criteria: * history of receiving any varicella-zoster virus vaccine * receipt of any vaccines within 6 weeks of first dose of study treatment. * subjects with current infections or history of infections. * history of recurrent (more than one episode) of herpes zoster or disseminated (a single episode) of herpes zoster or disseminated (a single episode) of herpes simplex.
effect of neem extract, propylene glycol and salicylic acid combination in the treatment of arsenical palmar keratosis

Conditions: Chronic Arsenic Poisoning

Summary: this study is designed to find out the effectiveness of combination of ethanol extract of neem leaf, propylene glycol (40%) and salicylic acid (10%) in the treatment of palmar arsenical keratosis.

arsenic, a non-essential trace element, is a major water pollutant in bangladesh. arsenical keratosis, which occurs in the palm and sole, is a common symptom of arsenicosis. the objective of this study is to find the effectiveness of combination of topical administration of the ethanol extract of leaf of neem (azadirachta indica), propylene glycol (40%) and salicylic acid (10%) in the treatment of palmar arsenical keratosis. on the basis of inclusion and exclusion criteria, 30 patients of moderate palmar arsenical keratosis will be recruited from an arsenic affected area. they will be divided into two groups: study group and placebo comparator group. each group consisting of 15 members. study group will be given combination of ethanol extract of leaf of neem, propylene glycol (40%) and salicylic acid (10%) to apply on palm overnight once daily for 12 weeks. on the other hand placebo comparator group will be given salicylic (10%) acid to apply on palm overnight once daily for 12 weeks. water and nail samples will be collected before starting recruitment to confirm arsenicosis. after conclusive recruitment of the subjects the objective, nature, purpose and potential risks and benefits of all procedures of the study will be explained in details to the patients and informed written consent will be taken from them. detail history, clinical examination and photograph (palm) will also be collected. clinical improvement will be assessed by measuring palmar nodular size on both hands, before starting treatment and after 12 weeks completion of treatment and perception of patients about their improvement. the study will explore the effectiveness of topical use of combination of ethanol extract of neem, propylene glycol and salicylic acid for the treatment of palmar arsenical keratosis.

Eligibility criteria:
inclusion criteria: * age: 18-60 years * palmar arsenical keratosis * drinking arsenic contaminated water (\>50 µg/l) for more than six months * patient voluntarily agree to participate exclusion criteria: * pregnancy and lactating mother * skin lesion :psoriasis and eczema * bowen's disease * any kind of systemic disease, inflammatory disease and infectious condition that affect skin (diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus , hepatitis and tuberculosis) * hypersensitivity to any drug * patient who received treatment within last three months
effect of treatment with metformin in type 2 diabetes patients on alternative genes splicing

Conditions: Type 2 Diabetes

Summary: main objective : show that treatment with metformin in patients with type 2 diabetes has an effect on alternative splicing of the insulin receptor. secondary objective : demonstrate that the effect on the ratio a/isoform b isoform with discontinuation of treatment with metformin can be réversé by the resumption of metformin treatment.


Eligibility criteria:
inclusion criteria: * type 2 diabetic patients usually treated with metformin (≥ 1400 mg/day), associated or not to other oral anti-diabetic treatment or. injection treatment * patients major. * patients with a social security number * patients having signed a consent to participate in the study exclusion criteria: * intolerance metformin * patients with type 1. * patients on pioglitazone or rosiglitazone * renal failure by an anomaly of the creatinine clearance (\< 60 ml/min). * patients pregnant or likely to be.
evaluate the clinical feasibility of a novel neoantigen-reactive cd8+ t cell (nart) detection technology for postoperative mrd surveillance of pancreatic cancer

Conditions: Minimal Residual Disease; Pancreatic Cancer Resectable

Summary: the goal of this observational study is to learn about the diagnostic performance of a novel neoantigen-reactive cd8+ t cell (nart) technology detecting minimal residual disease (mrd) in postoperative surveillance of pancreatic cancer. the main question it aims to answer is: is nart a sensitive and accurate detection for mrd? participants are required to undergo periodic blood sampling and imaging examinations as the protocol specifies.


Eligibility criteria:
inclusion criteria: * age \>18 * assessd as resectable pdac before surgical procedure * voluntary to donate tumor samples resected in curative surgery for pdac * voluntary to participate in the radiological evaluation, tests of serum tumor markers, and the collection of mrd samples according to the study protocol * ecog state (ps) grades ≤ 2 * voluntary to sign informed consent and adhering to the requirements and limitations outlined by lcd and this protocol * confimed as pancreatic ductal adenocarcinoma by pathology * ro or r1 resection * clinically evalutated eligible for adjuvant therapy * tumor tissue samples meet the requirements of whole exome sequencing (wes) exclusion criteria: * preoperative imaging examinations show distant metastasis * have received neoadjuvant therapy * have any other active malignancy within 5 years before enrollment, or have any other indolent cancers that did not interfere with the primary cancer assessment in the study without prior approval from the research committee * with other physical or mental conditions that may increase the risk of study participation or (in the investigator's judgment) may make the subject ineligible for study participation, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormalities * have participated in other interventional or observational clinical studies
an efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy

Conditions: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

Summary: the purpose of the study is to compare the efficacy of ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and gastro-esophageal cancer.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. key inclusion criteria: * histologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the gastric and gastro-esophageal junction * received first-line chemotherapy using fluoropyrimidine and platinum combination without disease progression * eastern cooperative oncology group (ecog) performance status of 0 or 1 * measurable disease by modified who criteria (unless complete response from previous chemotherapy) key exclusion criteria: * known human epidermal growth factor receptor2 (her2) positive status * radiological evidence of brain metastases * history of severe autoimmune or immune mediated disease requiring prolonged immunosuppressive treatment * inadequate hematologic, renal and hepatic function
comparison of the euploid rate of blastocyst between ppos and gnrh antagonist protocol in women with pcos undergoing pgt-a

Conditions: Preimplantation Genetic Testing; Progestin-primed Ovarian Stimulation; Polycystic Ovarian Syndrome; GnRH Antagonist

Summary: this randomized trial aims to compare the euploid rate of blastocysts between ppos (progestin-primed ovarian stimulation) and gnrh (gonadotrophin releasing hormone) antagonist protocols in patients with pcos (polycystic ovary syndrome) undergoing pgt-a (preimplantation genetic testing for aneuploidy). infertile women with pcos will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. eligible women will be randomised into one of the two groups: antagonist group: women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. ppos group: women will receive oral mpa (medroxyprogesterone acetate)10mg qd from day 3 till the day of ovulation trigger. the primary outcome is the euploidy rate of blastocysts.


Eligibility criteria:
inclusion criteria: * women age between 20 and 37 years. * women diagnosed with pcos according to the modified rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and/or ovarian volume \>10 ml on transvaginal ultrasonographic scanning, and/or clinical/ biochemical hyperandrogenism. other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded exclusion criteria: * presence of a functional ovarian cyst with e2\>100 pg/ml * endometriosis grade 3 or higher * repeated implantation failure (\>=4 embryos replaced or \>=2 blastocysts replaced without success) * women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s) * women who are indicated and planned to undergo pgt-sr (preimplantation genetic testing for structural rearrangement) or pgt-m (preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease; * recipient of oocyte donation * presence of hydrosalpinx which is not surgically treated
a study of retrovir in the prevention of hiv infection in health care workers accidentally exposed to the virus

Conditions: HIV Infections

Summary: to evaluate the safety and effectiveness of retrovir (azt) when used as prophylaxis for health care workers at risk for hiv infection from exposure to hiv-contaminated blood or blood components.


Eligibility criteria:
exclusion criteria co-existing condition: patients with the following are excluded: * a prior history of a malignancy other than cutaneous basal cell or cervical carcinomas. * other significant, chronic underlying medical illness which, in the physician's judgment, would impair study completion. * evidence of compromised bone marrow function (lab results) with a blood transfusion within the last month. * liver dysfunction as indicated by lab results. patients are excluded if there is a prior diagnosis of hiv infection by one of the following criteria: * hiv antibody positive by elisa and western blot assays or by other certified test method. (patients who are elisa positive but western blot or other confirmatory tests are negative may continue in study). * hiv antigen positive. * clinical symptoms which lead to a diagnosis by a licensed physician of aids or aids related complex or aids-related dementia. also excluded are individuals who have experienced similar hiv exposure as described in this protocol in the past month and individuals who have previously been enrolled in this study. the purpose of these exclusions is to eliminate possible seroconversion in an individual that could be attributed to hiv exposure other than the single exposure experienced just prior to entry into the study. prior medication: excluded within 4 weeks of study entry: * any potentially myelosuppressive drug. * nephrotoxic agent. * other experimental therapy. exposure of a health care worker to hiv-contaminated blood or blood component within 5 days prior to beginning therapy, defined as one of the following: * penetrating wound from needle recently removed from patient or sample container (e.g., blood bag, blood tube) or from sharp object visibly contaminated with hiv-positive blood or blood component. in the case of needlesticks or cuts with sharp objects, blood or blood component must not have been exposed to the air for more than 1 hour. if actual infusion of blood occurs, the 1-hour time limit does not apply. * hypodermic needles should come in contact with the blood and blood component from an hiv source but need not be visibly contaminated with blood to be considered a source of contamination. * significant exposure to hiv-positive blood or blood component as the result of splash on abraded skin. * significant exposure to hiv-positive blood or blood component as the result of splash on mucous membranes. * participant must be able to give informed consent. active drug or alcohol abuse sufficient in the physician's opinion to prevent compliance with the study regimen.

Keywords: health manpower accidents, occupational zidovudine